J8P.F Cinclus Pharma Holding AB (publ)
- Market cap
- EUR 46.7M
- P/E
- -
- P/B
- 2.67x
- ROE
- -165.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is J8P.F undervalued?
Graham numberThe Graham number of Cinclus Pharma Holding AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cinclus Pharma Holding AB (publ) fundamental analysis
No fundamental analysis for Cinclus Pharma Holding AB (publ) yet.
Cinclus Pharma Holding AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cinclus Pharma Holding AB (publ)
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylor…
Full company profileCinclus Pharma Holding AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cinclus Pharma Holding AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 10.6M | 5.96M | 4.58M | 57.5M | 23.6M |
| Operating Income | -84.3M | -211M | -200M | -169M | -198M | -372M |
| EBITDA | - | -230M | -206M | -157M | -181M | -368M |
| Net Income | -76.3M | -249M | -215M | -168M | -184M | -335M |
| EPS | -1.64 | -5.35 | -4.62 | -3.61 | -3.95 | -7.20 |
| Balance Sheet | ||||||
| Total Assets | 147M | 186M | 94.4M | 601M | 547M | 425M |
| Total Liabilities | 20.1M | 58.9M | 171M | 45.7M | 177M | 222M |
| Shareholders' Equity | 127M | 127M | -76.8M | 555M | 369M | 203M |
| Cash & Short-term Investments | 138M | 174M | 88.0M | 567M | 487M | 388M |
| Cash Flow | ||||||
| Operating Cash Flow | -75.4M | -192M | -209M | -178M | -74.6M | -364M |
| Capital Expenditure | 131K | 0.00 | 0.00 | 0.00 | 1.13M | 48.0K |
| Free Cash Flow | -75.5M | -192M | -209M | -178M | -75.8M | -364M |
| Ratios | ||||||
| ROE | -60.0% | -196.3% | - | -30.3% | -49.8% | -165.3% |
| ROA | -51.8% | -134.1% | -227.8% | -28.0% | -33.7% | -78.9% |
| Net Profit Margin | - | -2,356.2% | -3,610.0% | -3,668.8% | -320.1% | -1,419.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cinclus Pharma Holding AB (publ) dividends
Cinclus Pharma Holding AB (publ) has not paid dividends in the last 5 fiscal years.
Who owns Cinclus Pharma Holding AB (publ)
- Insiders 29.95%
- Institutions 36.42%
- Public & others 33.62%
- Shares outstanding 46.5M
- Free float 34.3M
Cinclus Pharma Holding AB (publ) company profile
- Company name
- Cinclus Pharma Holding AB (publ)
- Ticker
- J8P.F
- ISIN
- SE0020388577
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 17
- Fiscal year end
- December
- Address
- Kungsbron 1, Elevator G, Stockholm, Sweden, 11122
- Phone
- 46 8 13 33 10
- Website
- cincluspharma.com
About Cinclus Pharma Holding AB (publ)
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
Cinclus Pharma Holding AB (publ) management
8- Dr. Lennart Hansson Ph.D.Co-founder & Chairman of the Board · born 1956
- Mr. Christer AhlbergCEO & President · born 1971
- Mr. Peter UngeCo-founder & Member of Scientific Advisory Board · born 1951
- Mr. Magnus ChristensenChief Financial Officer · born 1974
- Ms. Kajsa LarssonChief Medical Officer · born 1966
- Mr. Jesper WiklundChief Business Officer · born 1969
- Mr. Peter WallichChief Commercial Officer & Commercial Director · born 1961
- Dr. Margit Mahlapuu Ph.D.Executive R&D Director · born 1972